Mechanism of the Cardioprotective Effect of Transforming Growth Factor Beta 1 in Feline Myocardial Ischemia and Reperfusion

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1993 Feb 1

PMID 8381531

Citations 27

Authors

A M Lefer

X L Ma

A S Weyrich

R Scalia

Affiliations

Soon will be listed here.

Abstract

We studied the effects of transforming growth factor beta 1 (TGF-beta 1) in a feline model of myocardial ischemia (1.5 hr) and reperfusion (4.5 hr). Myocardial ischemia followed by reperfusion resulted in severe myocardial injury, endothelial dysfunction, high cardiac myeloperoxidase activity indicative of neutrophil accumulation in the ischemic myocardium, and significant neutrophil adherence to the ischemic coronary endothelium. In contrast, intravenous administration of TGF-beta 1 (20 micrograms/kg) 30 min prior to reperfusion significantly attenuated myocardial necrosis (13.8% +/- 3.5% vs. 32.2% +/- 2.9% of area-at-risk, P < 0.01) and attenuated endothelial dysfunction (P < 0.01) associated with ischemia-reperfusion. Moreover, myeloperoxidase activity in the ischemic myocardium was significantly lower than vehicle controls (0.2 +/- 0.1 vs. 1.7 +/- 0.3 units/100 mg of tissue, P < 0.01) and neutrophil adherence to ischemic coronary endothelium was significantly (P < 0.01) attenuated in TGF-beta 1-treated cats. These results demonstrate that TGF-beta 1 exerts a significant cardioprotective effect in a feline model of myocardial ischemia and reperfusion. The mechanism of this protective effect appears to relate to endothelial preservation by TGF-beta 1 inhibiting circulating neutrophils from adhering to the endothelium, a critical step in neutrophil-induced reperfusion injury.

Citing Articles

Cardiomyocyte-Restricted Expression of IL11 Causes Cardiac Fibrosis, Inflammation, and Dysfunction.

Sweeney M, OFee K, Villanueva-Hayes C, Rahman E, Lee M, Vanezis K Int J Mol Sci. 2023; 24(16).

PMID: 37629170 PMC: 10455677. DOI: 10.3390/ijms241612989.

Transforming growth factor-β in myocardial disease.

Frangogiannis N Nat Rev Cardiol. 2022; 19(7):435-455.

PMID: 34983937 DOI: 10.1038/s41569-021-00646-w.

Resveratrol Protects Cardiac Tissue in Experimental Malignant Hypertension Due to Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Properties.

Grujic-Milanovic J, Jacevic V, Miloradovic Z, Jovovic D, Milosavljevic I, Milanovic S Int J Mol Sci. 2021; 22(9).

PMID: 34066865 PMC: 8125904. DOI: 10.3390/ijms22095006.

Apelin/APJ signaling suppresses the pressure ulcer formation in cutaneous ischemia-reperfusion injury mouse model.

Yamazaki S, Sekiguchi A, Uchiyama A, Fujiwara C, Inoue Y, Yokoyama Y Sci Rep. 2020; 10(1):1349.

PMID: 31992828 PMC: 6987197. DOI: 10.1038/s41598-020-58452-2.

The Role of the TGF-β Superfamily in Myocardial Infarction.

Hanna A, Frangogiannis N Front Cardiovasc Med. 2019; 6:140.

PMID: 31620450 PMC: 6760019. DOI: 10.3389/fcvm.2019.00140.

References

Weissmann G . The role of neutrophils in vascular injury: a summary of signal transduction mechanisms in cell/cell interactions. Springer Semin Immunopathol. 1989; 11(3):235-58. DOI: 10.1007/BF00197305. View

Johnson 3rd G, Tsao P, Mulloy D, Lefer A . Cardioprotective effects of acidified sodium nitrite in myocardial ischemia with reperfusion. J Pharmacol Exp Ther. 1990; 252(1):35-41. View

Lefer A, Tsao P, Aoki N, Palladino Jr M . Mediation of cardioprotection by transforming growth factor-beta. Science. 1990; 249(4964):61-4. DOI: 10.1126/science.2164258. View

Tsao P, Aoki N, Lefer D, Johnson 3rd G, Lefer A . Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation. 1990; 82(4):1402-12. DOI: 10.1161/01.cir.82.4.1402. View

Yuan Y, Fleming B . A method for isolation and fluorescent labeling of rat neutrophils for intravital microvascular studies. Microvasc Res. 1990; 40(2):218-29. DOI: 10.1016/0026-2862(90)90021-i. View

Lefer A, Tsao P, Lefer D, Ma X . Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J. 1991; 5(7):2029-34. DOI: 10.1096/fasebj.5.7.2010056. View

Ma X, Tsao P, Viehman G, Lefer A . Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion-reperfused cat coronary artery. Circ Res. 1991; 69(1):95-106. DOI: 10.1161/01.res.69.1.95. View

McEver R . GMP-140: a receptor for neutrophils and monocytes on activated platelets and endothelium. J Cell Biochem. 1991; 45(2):156-61. DOI: 10.1002/jcb.240450206. View

Ma X, Tsao P, Lefer A . Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest. 1991; 88(4):1237-43. PMC: 295592. DOI: 10.1172/JCI115427. View

10.

Lefer A . Mechanisms of the protective effects of transforming growth factor-beta in reperfusion injury. Biochem Pharmacol. 1991; 42(7):1323-7. DOI: 10.1016/0006-2952(91)90441-7. View

11.

Karasawa A, Guo J, Ma X, Lefer A . Beneficial effects of transforming growth factor-beta and tissue plasminogen activator in splanchnic artery occlusion and reperfusion in cats. J Cardiovasc Pharmacol. 1991; 18(1):95-105. DOI: 10.1097/00005344-199107000-00013. View

12.

Ma X, Johnson 3rd G, Lefer A . Low doses of superoxide dismutase and a stable prostacyclin analogue protect in myocardial ischemia and reperfusion. J Am Coll Cardiol. 1992; 19(1):197-204. DOI: 10.1016/0735-1097(92)90073-v. View

13.

Ma X, Lefer D, Lefer A, Rothlein R . Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation. 1992; 86(3):937-46. DOI: 10.1161/01.cir.86.3.937. View

14.

Lefer D, Nakanishi K, Vinten-Johansen J, Ma X, Lefer A . Cardiac venous endothelial dysfunction after myocardial ischemia and reperfusion in dogs. Am J Physiol. 1992; 263(3 Pt 2):H850-6. DOI: 10.1152/ajpheart.1992.263.3.H850. View

15.

Bradley P, Priebat D, Christensen R, ROTHSTEIN G . Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982; 78(3):206-9. DOI: 10.1111/1523-1747.ep12506462. View

16.

Assoian R, Komoriya A, Meyers C, Miller D, Sporn M . Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983; 258(11):7155-60. View

17.

Frolik C, Dart L, Meyers C, Smith D, Sporn M . Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A. 1983; 80(12):3676-80. PMC: 394113. DOI: 10.1073/pnas.80.12.3676. View

18.

Roberts A, Anzano M, Meyers C, Wideman J, Blacher R, Pan Y . Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry. 1983; 22(25):5692-8. DOI: 10.1021/bi00294a002. View

19.

Massague J, Like B . Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J Biol Chem. 1985; 260(5):2636-45. View

20.

Mullane K, Kraemer R, Smith B . Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods. 1985; 14(3):157-67. DOI: 10.1016/0160-5402(85)90029-4. View